990510-9
IPEA COPY + -
REPLACEMENT
SHEETS

**PCT** WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 217/04, 405/06, 401/06, 409/06, A61K 31/47

A1

(11) International Publication Number: WO 98/23593

(43) International Publication Date: 4 June 1998 (04.06.98)

(21) International Application Number: PCT/IB97/01368

(22) International Filing Date: 3 November 1997 (03.11.97)

(30) Priority Data:
60/032,307 27 November 1996 (27.11.96) US

(71) Applicant *(for all designated States except US)*: PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).


(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: CHANG, George [US/US]; 1 Winthrop Hill Road, Ivoryton, CT 06442 (US). QUALLICH, George, Joseph [US/US]; 349 Norwich Westerly Road, North Stonington, CT 06359 (US).

(74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

**Published**
*With international search report.*

(54) Title: APO B–SECRETION/MTP INHIBITORY AMIDES




(I)

(57) Abstract

This invention is directed to compounds of formula (I) or the stereoisomers, pharmaceutically acceptable salts and hydrates thereof. The compounds are Apo B/MTP inhibitors and are useful in the treatment of various disorders and conditions such as atherosclerosis, pancreatitis, obesity, hypercholesteremia, hypertriglyceridemia, hyperlipidemia, and diabetes. The compounds of this invention are also useful in combination with other pharmaceutical agents including cholesterol biosynthesis inhibitors and cholesterol absorption inhibitors, especially HMG–CoA reductase inhibitors and HMG–CoA synthase inhibitors; HMG–CoA reductase gene expression inhibitors; CETP inhibitors; bile acid sequestrants; fibrates; cholesterol absorption inhibitors; ACAT inhibitors, squalene synthetase inhibitors, ion–exchange resins, anti–oxidants and niacin. This invention is also directed to intermediates and processes useful in the preparation of compounds of formula (I).